Durability of Pulmonary Valve Replacement with Large Diameter Stented Porcine Bioprostheses

      There is limited information about durability of large diameter porcine bioprostheses implanted for pulmonary valve replacement (PVR). We studied patients who underwent surgical PVR from 2002-2019 with a stented porcine bioprosthetic valve (BPV) with a labeled size ≥27 mm. The primary outcome was freedom from reintervention. During the study period, 203 patients underwent PVR using a porcine BPV ≥27 mm, 94% of whom received a Mosaic valve (Medtronic Inc., Minneapolis, MN). Twenty patients underwent reintervention from 3.4-12.0 years after PVR: 5 surgical and 15 transcatheter PVR procedures. The indication for reintervention was regurgitation in 13 patients, stenosis in 2, mixed disease in 4, and endocarditis in 1. Estimated freedom from reintervention was 97±1% at 5 years and 82±4% at 10 years, and freedom from prosthesis dysfunction (moderate or severe regurgitation and/or a maximum Doppler gradient ≥50 mm Hg) over time was 91±2% at 5 years and 74±4% at 10 years. Younger age and smaller true valve diameter were associated with shorter freedom from reintervention, but valve oversizing was not. The durability of large stented porcine bioprostheses in the pulmonary position is generally excellent, particularly in adolescents and adults, similar to various other types of BPV. In the current study, relative valve size was not associated with valve longevity, although the low event-rate in this population was a limiting factor.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seminars in Thoracic and Cardiovascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bowman Jr, F.O.
        • Hancock W.D.
        • Malm J.R.
        A valve-containing dacron prosthesis. Its use in restoring pulmonary artery-right ventricular continuity.
        Arch Surg. 1973; 107: 724-728
        • Lee C.
        • Park C.S.
        • Lee C.H.
        • et al.
        Durability of bioprosthetic valves in the pulmonary position: long-term follow-up of 181 implants in patients with congenital heart disease.
        J Thorac Cardiovasc Surg. 2011; 142: 351-358
        • Chen P.C.
        • Sager M.S.
        • Zurakowski D.
        • et al.
        Younger age and valve oversizing are predictors of structural valve deterioration after pulmonary valve replacement in patients with tetralogy of Fallot.
        J Thorac Cardiovasc Surg. 2012; 143: 352-360
        • Batlivala S.P.
        • Emani S.
        • Mayer J.E.
        • et al.
        Pulmonary valve replacement function in adolescents: a comparison of bioprosthetic valves and homograft conduits.
        Ann Thorac Surg. 2012; 93: 2007-2016
        • Jang W.
        • Kim Y.J.
        • Choi K.
        • et al.
        Mid-term results of bioprosthetic pulmonary valve replacement in pulmonary regurgitation after tetralogy of Fallot repair.
        Eur J Cardiothorac Surg. 2012; 42: e1-e8
        • Abbas J.R.
        • Hoschtitzky J.A.
        Which is the best tissue valve used in the pulmonary position, late after previous repair of tetralogy of Fallot?.
        Interact Cardiovasc Thorac Surg. 2013; 17: 854-860
        • Chen X.J.
        • Smith P.B.
        • Jaggers J.
        • et al.
        Bioprosthetic pulmonary valve replacement: contemporary analysis of a large, single-center series of 170 cases.
        J Thorac Cardiovasc Surg. 2013; 146: 1461-1466
        • Giamberti A.
        • Chessa M.
        • Reali M.
        • et al.
        Porcine bioprosthetic valve in the pulmonary position: mid-term results in the right ventricular outflow tract reconstruction.
        Pediatr Cardiol. 2013; 34: 1190-1193
        • McKenzie E.D.
        • Khan M.S.
        • Dietzman T.W.
        • et al.
        Surgical pulmonary valve replacement: a benchmark for outcomes comparisons.
        J Thorac Cardiovasc Surg. 2014; 148: 1450-1453
        • Neukamm C.
        • Lindberg H.L.
        • Try K.
        • et al.
        Pulmonary valve replacement with a bovine pericardial valve: a five year follow-up study.
        World J Pediatr Congenit Heart Surg. 2014; 5: 534-540
        • Schubert S.A.
        • Myers J.L.
        • Kunselman A.R.
        • et al.
        Early outcomes of pulmonary valve replacement with the mitroflow bovine pericardial bioprosthesis.
        Ann Thorac Surg. 2015; 99: 1692-1698
        • Shinkawa T.
        • Lu C.K.
        • Chipman C.
        • et al.
        The midterm outcomes of bioprosthetic pulmonary valve replacement in children.
        Semin Thorac Cardiovasc Surg. 2015; 27: 310-318
        • Kwak J.G.
        • Lee C.
        • Lee M.
        • et al.
        Does implantation of larger bioprosthetic pulmonary valves in young patients guarantee durability in adults? Durability analysis of stented bioprosthetic valves in the pulmonary position in patients with Tetralogy of Fallot†.
        Eur J Cardiothorac Surg. 2016; 49: 1207-1212
        • Nomoto R.
        • Sleeper L.A.
        • Borisuk M.J.
        • et al.
        Outcome and performance of bioprosthetic pulmonary valve replacement in patients with congenital heart disease.
        J Thorac Cardiovasc Surg. 2016; 152: 1333-1342
        • Gulack B.C.
        • Benrashid E.
        • Jaquiss R.D.
        • et al.
        Pulmonary valve replacement with a Trifecta valve is associated with reduced transvalvular gradient.
        Ann Thorac Surg. 2017; 103: 655-662
        • Corno A.F.
        • Dawson A.G.
        • Bolger A.P.
        • et al.
        Trifecta St. Jude medical® aortic valve in pulmonary position.
        Nano Rev Exp. 2017; 81299900
        • Bell D.
        • Prabhu S.
        • Betts K.S.
        • et al.
        Long-term performance of homografts versus stented bioprosthetic valves in the pulmonary position in patients aged 10-20 years.
        Eur J Cardiothorac Surg. 2018; 54: 946-952
        • Yuen C.S.
        • Lee K.F.L.
        • Bhatia I.
        • et al.
        Porcine versus pericardial pulmonary valve replacement in adults with prior congenital cardiac surgery: midterm outcomes.
        World J Pediatr Congenit Heart Surg. 2019; 10: 197-205
        • Bapat V.N.
        • Attia R.
        • Thomas M.
        Effect of valve design on the stent internal diameter of a bioprosthetic valve: a concept of true internal diameter and its implications for the valve-in-valve procedure.
        JACC Cardiovasc Interv. 2014; 7: 115-127
        • Haycock G.B.
        • Schwartz G.J.
        • Wisotsky D.H.
        Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.
        J Pediatr. 1978; 93: 62-66
        • Sluysmans T.
        • Colan S.D.
        Theoretical and empirical derivation of cardiovascular allometric relationships in children.
        J. Appl. Physiol. 2005; 99: 445-457
        • Karamlou T.
        • Ungerleider R.M.
        • Alsoufi B.
        • et al.
        Oversizing pulmonary homograft conduits does not significantly decrease allograft failure in children.
        Eur J Cardiothorac Surg. 2005; 27: 548-553
        • Karamlou T.
        • Blackstone E.H.
        • Hawkins J.A.
        • et al.
        Pulmonary conduit working group for the members of the congenital heart surgeons society. can pulmonary conduit dysfunction and failure be reduced in infants and children less than age 2 years at initial implantation?.
        J Thorac Cardiovasc Surg. 2006; 132: 829-838
        • Nordmeyer J.
        • Tsang V.
        • Gaudin R.
        • et al.
        Quantitative assessment of homograft function 1 year after insertion into the pulmonary position: impact of in situ homograft geometry on valve competence.
        Eur Heart J. 2009; 30: 2147-2154
        • Capps S.B.
        • Elkins R.C.
        • Fronk D.M.
        Body surface area as a predictor of aortic and pulmonary valve diameter.
        J Thorac Cardiovasc Surg. 2000; 119: 975-982
        • Cabalka A.K.
        • Asnes J.D.
        • Balzer D.T.
        • et al.
        Transcatheter pulmonary valve replacement using the melody valve for treatment of dysfunctional surgical bioprostheses: A multicenter study.
        J Thorac Cardiovasc Surg. 2018; 155: 1712-1724
        • McElhinney D.B.
        • Cheatham J.P.
        • Jones T.K.
        • et al.
        Stent fracture, valve dysfunction, and right ventricular outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and procedural risk factors in the US Melody valve trial.
        Circ Cardiovasc Interv. 2011; 4: 602-614
        • Morray B.H.
        • McElhinney D.B.
        • Cheatham J.P.
        • et al.
        Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: a multicenter experience.
        Circ Cardiovasc Interv. 2013; 6: 535-542
        • Zahn E.M.
        Self-expanding pulmonary valves for large diameter right ventricular outflow tracts.
        Interv Cardiol Clin. 2019; 8: 73-80
        • Shahanavaz S.
        • Asnes J.D.
        • Grohmann J.
        • et al.
        Intentional fracture of bioprosthetic valve frames in patients undergoing valve-in-valve transcatheter pulmonary valve replacement.
        Circ Cardiovasc Interv. 2018; 11e006453

      Linked Article

      • Commentary: Upsizing the Potential Performance of Pulmonary Valve Prostheses
        Seminars in Thoracic and Cardiovascular SurgeryVol. 34Issue 3
        • Preview
          Dr Maeda and colleagues from Stanford University present excellent outcomes from their institutional practice of using large stented porcine bioprosthetic valves (ie, ≥27 mm diameter) for pulmonary valve replacement surgeries in pediatric and adult patients (PVR).1 Their large patient population from over a long 17-year study period included a mean age range of 10–49 years, though over 60% of patients were 18 years or older. Patient follow-up was very complete with a modest median interval of 6.5 years.
        • Full-Text
        • PDF